CVS's $315 million opioid settlement lets the pharmacy chain block suspicious prescribers — but what happens to patients left without care? A new op-ed argues that stopping unsafe dispensing isn't enough if patients aren't safely transitioned to appropriate treatment. Independent outcome tracking could be the missing piece.
CVS recently reached a $315 million federal opioid settlement resolving allegations of unlawful dispensing and false claims. As part of the deal, a DEA memorandum now requires CVS to block controlled-substance prescriptions from prescribers whose licenses have been suspended or revoked — and to block any prescriber across its retail pharmacies when unresolved concerns arise. But the agreement stops short of requiring any assessment of what happens to patients after those blocks go into effect.
That gap is the crux of a new op-ed by epidemiologist Alex Smolak, PhD. He argues that restricting a dangerous prescriber and protecting the patient are two separate — but equally important — goals. Patients cut off from opioid prescriptions may face severe withdrawal, uncontrolled pain, or even mental health crises, especially if they don't receive a managed transition to safer care. FDA warnings and CDC guidance both caution against abrupt opioid discontinuation, and a large JAMA study found that tapering long-term opioid patients was linked to increased overdose and mental health crisis rates.
Key Takeaways:
Why it matters: Blocking a bad actor at the pharmacy counter is a necessary step — but without tracking what happens next, we can't know if patients are getting better care or simply falling through the cracks.
